Transcription factor IIA (TFIIA) is a positive acting general factor that contacts the TATA-binding protein (TBP) and mediates an activator-induced conformational change in the transcription factor IID (TFIID) complex. Previously, we have found that phosphorylation of yeast TFIIA stimulates TFIIA⅐TBP⅐TATA complex formation and transcription activation in vivo. We now show that human TFIIA is phosphorylated in vivo on serine residues that are partially conserved between yeast and human TFIIA large subunits. Alanine substitution mutation of serine residues 316 and 321 in TFIIA ␣␤ reduced TFIIA phosphorylation significantly in vivo. Additional alanine substitutions at serines 280 and 281 reduced phosphorylation to undetectable levels. Mutation of all four serine residues reduced the ability of TFIIA to stimulate transcription in transient transfection assays with various activators and promoters, indicating that TFIIA phosphorylation is required globally for optimal function. In vitro, holo-TFIID and TBP-associated factor 250 (TAF II 250) phosphorylated TFIIA on the ␤ subunit. Mutation of the four serines required for in vivo phosphorylation eliminated TFIID and TAF II 250 phosphorylation in vitro. The NH 2 -terminal kinase domain of TAF II 250 was sufficient for TFIIA phosphorylation, and this activity was inhibited by full-length retinoblastoma protein but not by a retinoblastoma protein mutant defective for TAF II 250 interaction or tumor suppressor activity. TFIIA phosphorylation had little effect on the TFIIA⅐TBP⅐TATA complex in electrophoretic mobility shift assay. However, phosphorylation of TFIIA containing a ␥ subunit Y65A mutation strongly stimulated TFIIA⅐TBP⅐TATA complex formation. TFIIA-␥Y65A is defective for binding to the ␤-sheet domain of TBP identified in the crystal structure. These results suggest that TFIIA phosphorylation is important for strengthening the TFIIA⅐TBP contact or creating a second contact between TFIIA and TBP that was not visible in the crystal structure.
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TFIIA
1 was identified originally as an activity required for optimal in vitro transcription with HeLa cell nuclear extracts and various viral and cellular templates (1) (reviewed in Refs. [2] [3] [4] [5] . TFIIA was isolated as three polypeptides from human and Drosophila embryo extracts, and the two largest subunits are proteolytic cleavage products of a single open reading frame (6 -13) . TFIIA could be purified as a TATA-binding protein (TBP)-associated factor, although it could also be found as a chromatographically separate complex from TBP (7) . In addition to binding directly to TBP, TFIIA stabilized the binding of TBP with TATA DNA in electrophoretic mobility shift assays (EMSA) (14, 15) . In transcription reactions reconstituted with partially purified general factors and coactivators, TFIIA is essential for activator-mediated transcription and has a weak stimulatory effect on basal transcription lacking exogenous activators. In transcription reactions reconstituted with recombinant and affinity-purified general factors and coactivators, TFIIA is dispensable (16, 17) . Based on these findings, TFIIA is thought to be a transcription accessory factor required for complex regulation in the presence of positive and negative cofactors in vivo. The two genes encoding the polypeptides of TFIIA share significant sequence similarity between human and yeast Saccharomyces cerevisiae (18) . The yeast TFIIA genes, TOA1 and TOA2, are both essential for viability (19) . Reduction of TOA1 expression results in a general 2-fold decrease in RNA polymerase II transcription, although some genes are more dramatically affected and others are elevated in gene expression (20, 21) . Depletion of TOA1 led to a cell cycle arrest at the G 2 /M border but did not have a dramatic affect on transcription activation by several activators. TOA2 mutants compromised for TBP binding were defective for transcription activation with several activators and promoters and also accumulated at the G 2 /M border (22) . In this respect, TFIIA behaves similar to several TAFs that when depleted have limited effect on global gene expression but result in cell cycle arrest.
Cross-talk between TFIIA and the largest TAF (human TAF II 250 and yeast TAF II 145) has been described both biochemically and genetically (23) (24) (25) . The amino-terminal domain of TAF II 250 contains a negative regulatory element that binds TBP competitively with TFIIA (23, 26, 27) . TAF II 250 can inhibit TBP-TATA binding, and TFIIA can reverse this inhibition in a competitive manner (26) . Deletion of the amino-terminal domain of yeast TAF II 145 results in temperature-sensitive growth defects that can be suppressed by high copy expression of both subunits of TFIIA, supporting a genetic interaction of these two proteins in vivo (23) . TFIIA interacts with several other positive and negative transcriptional cofac-tors. TFIIA binds to the positive cofactor PC4 and is required in PC4-mediated transcription reactions in vitro (28) . TFIIA can stimulate transcription repressed by several negative cofactors, including NC2 (DR1/DRAP1), Mot1, and NC1 (TopoI) (29 -32) . The interaction between TFIIA and NC2 has been clearly established by yeast genetic experiments where a point mutation in TFIIA relieves the requirement for the otherwise essential DR1(Ydr1) and DRAP1(Bur6) genes (33) . This point mutation in TFIIA suppresses a slow growth phenotype induced by a reduced expression of DR1. Thus, TFIIA plays an important role in the balance between positive and negative acting cofactors of transcription.
Post-translational modifications of transcription factors and chromatin components have been shown to be important in transcription regulation. TAF II 250 possesses histone acetyltransferase activity and protein kinase activity (34, 35) . The kinase domain of TAF II 250 has been mapped to two distinct regions spanning the amino-terminal and carboxyl-terminal domains (35, 36) . The amino-terminal kinase domain of TAF II 250 has been shown to be capable of phosphorylating the 74-kDa subunit of RAP74 and, to a lesser extent, the large subunit of TFIIA (35, 36) . The retinoblastoma (Rb) tumor suppressor protein can bind to the amino-terminal domain of TAF II 250 and inhibit kinase activity (37, 38) . TAF II 250 plays an important role in cell cycle progression in mammalian cells, since a point mutation in the central domain is responsible for the G 1 /S arrest in ts13 hamster cells (39, 40) . Whether Rb binding to TAF II 250 or the kinase activity of TAF II 250 contributes to cell cycle function is unclear.
In previous work, we demonstrated that yeast TFIIA was phosphorylated on the C-terminal domain of the large subunit (TOA1) in vivo (41) . Substitution of three serine residues in TOA1 resulted in the complete loss of TFIIA phosphorylation. TFIIA mutants incapable of being phosphorylated were reduced for T-A binding in vitro and incapable of high level transcription activation in vivo at some promoters. While phosphorylation-defective TFIIA did not lead to an apparent growth defect, the serine to alanine mutations were lethal when combined with a single alanine substitution in a second position known to contact TBP. (42, 43) . Mutagenesis of these residues reduced T-A complex formation and had growth defects in vivo (22, 44) . However, mutagenesis experiments suggest that additional residues in the basic repeat region of helix H2 in TBP were important for T-A complex formation (45, 46) . The crystal structure did not detect a clear contact between TFIIA and these residues, although in one structure a nonresolvable electron density appeared near TBP helix H2 (42) . A substantial region of TOA1 was not structured in the ternary complex and therefore could not be assigned a fixed position. Recently, two NMR studies suggest that the unstructured region of TFIIA can contact helix H2 of TBP (27, 47) . We present evidence here that phosphorylation of TFIIA on serine residues in the unstructured domain of TOA1 (human TFIIA ␤) stabilizes the T-A complex when the primary contact is disrupted. Phosphorylation competent TFIIA stimulated transcription in transient transfection assays, suggesting that phosphorylation is important for high level transcription in vivo. Finally, we present evidence that TAF II 250 amino-terminal kinase domain can phosphorylate TFIIA on serine residues known to be phosphorylated in vivo.
MATERIALS AND METHODS
Plasmid Constructs and Yeast Strains-The FLAG-tagged ␣␤ subunit of human TFIIA was expressed in transient transfection assays using the plasmid pFLAGhIIA␣␤ (gift of J. Zhang, University of Pennsylvania, Philadelphia, PA and M. Lazar, University of Medicine and Dentistry of New Jersey, Piscataway, NJ), and the ␥ subunit of TFIIA was expressed using pCMV-hIIA␥ (gift of D. Reinberg) (8) . Some or all of the codons for the four serine residues at sites 280, 281, 316, and 321 of the ␣␤ gene of pFLAGhIIA␣␤ were changed to those for alanine using the QuikChange site-directed mutagenesis kit (Stratagene), according to the manufacturer's instructions. This yielded plasmids pSPS762 (S280/281A), pSPS806 (S316/321A), and pSPS825 (S280/281/316/321A), all confirmed by sequencing. Expression plasmids expressing GAL4 DNA binding domains fused to the activation domains of E2F, EWS, VP16, or Myc were gifts of (F. Rauscher III and S. McMahon). The control plasmid pFLAG-CMV-2 was purchased from Sigma. The pG5-TK-Luc plasmid contains five GAL4 binding sites cloned upstream of the herpes simplex virus thymidine kinase core promoter regulating luciferase (gift of M. Lazar). The pCD1-76Luc promoter contains the cyclin D1 core promoter sequence Ϫ76 to ϩ45 regulating luciferase expression (gift of R. Pestell, Albert Einstein College of Medicine, New York). Experiments involving the Zta activator used pZtaSR␣ to express the activator (48) and pZ 7 E4TCAT as the reporter gene (49) . The eukaryotic expression vector for hTAF II 250 was obtained from E. Wang and R. Tjian (University of California, Berkley, CA).
Preparation of Proteins-Recombinant human TBP was isolated as an amino-terminal tagged hexahistidine fusion protein (gift of T. Curran, St. Judes Children's Research Hospital, Memphis, TN). The tagged TBP was expressed in Escherichia coli, purified on a Ni 2ϩ -nitrilotriacetic acid-agarose column (Qiagen), and renatured as described previously (26) . Recombinant hexahistidine-tagged human TFIIA ␣␤ protein was expressed in E. coli using the pQEhIIA␣␤ plasmid (11, 44) and isolated as described above. The hexahistidine-tagged human TFIIA ␥ protein or ␥ protein with tyrosine 65 mutated to alanine (␥Y65A) was expressed using pQEhIIA␥ (11, 44) and isolated as described above. To make recombinant ␣␤ ϩ ␥ or ␣␤ ϩ ␥Y65A for either in vitro phosphorylation or EMSA, the proteins were renatured in equimolar amounts, as referenced above. Casein kinase II from rat liver was acquired from Sigma. GST-Rb, GST-Rb⌬22, and the control GST proteins were expressed using pGEX-(GST)-Rb 379 -928 , pGEX(GST)-Rb 379 -928 ⌬ex22 (gifts of P. Robbins (37)), and pGEX-2T (Amersham Pharmacia Biotech), respectively. Purification of these GST-fused proteins was described previously (11) . Hemagglutinin epitope-tagged TAF II 250 and GST-TAF II 250-NTK were expressed as baculovirus proteins in Sf9 cells (gifts of R. Tjian) and isolated from lysate by immunoprecipitating with 12CA5 monoclonal antibody as described previously (50) or glutathioneSepharose beads. Human holo-TFIID was isolated from LTR3 cell lysate using the 12CA5 antibody as described (50) . Recombinant RAP74, a subunit of TFIIF, was made using expression plasmids obtained from D. Reinberg.
DNA Binding Reactions-Electrophoretic mobility shift assays were regularly performed in 12.5 mM Hepes, pH 7.9, 12.5% glycerol, 0.4 mg/ml bovine serum albumin, 6 mM MgCl 2 , 16 g/ml poly(dGdC:dGdC), 0.4% ␤-mercaptoethanol (12.5 l final volume) using the adenovirus E1B TATA box as a probe (51) . Binding reactions were done for 50 min at 30°C, separated on a 0.5ϫ TBE, 5% acrylamide gel, and visualized by autoradiography. When recombinant TFIIA was incubated with a kinase prior to EMSA, the treatment was performed in the same concentrations of Hepes, pH 7.9, bovine serum albumin, MgCl 2 , dGdC: dGdC oligonucleotide, glycerol, and ␤-mercaptoethanol, as described above. A final concentration of 2 units/ml CKII (Sigma) was used or the indicated amount of TAF II 250 NH 2 -terminal kinase and 100 M ATP, if required, in a 30-min incubation at 30°C. The DNA probe and other components of the binding reaction were then added, and the assay continued.
Transient Transfections-Transient transfections were performed using a modified CaPO 4 transfection protocol (52) . BHK21 or 293 cells were used, as indicated, and always grown at 37°C in 5% CO 2 . Cells were harvested 48 h after transfection and assayed using the Luciferase Assay System from Promega or a chloramphenicol acetyl transferase assay (48) .
In Vivo Phospholabeling-Metabolic labeling of phosphorylated proteins was performed on 293 cells, essentially as described previously (53) . Briefly, 24 h after transfection, the cells were washed with phosphate-free Dulbecco's modified Eagle's medium containing 10% dialyzed fetal bovine serum and 1ϫ penicillin-streptomycin-glutamine (all from Cellgro) and then refed with this same medium. 2 h later, [ 32 P]orthophosphate (200 Ci per ml of medium; PerkinElmer Life Sciences) was added, and growth continued for an additional 2 h. The plates were then set on ice and washed twice with ice-cold phosphatebuffered saline and then lysed with radioimmune precipitation buffer (1% Nonidet P-40, 1% deoxycholic acid, 0.1% SDS, 150 mM NaCl, 10 mM Tris-HCl, pH 7.4) with phosphatase and proteinase inhibitors (1 mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate, 2 g/ml pepstatin A, and 2 g/ml leupeptin) in an amount one-tenth of the volume of the medium used. After incubating for 15 min on ice, the lysate was removed to an Eppendorf tube and spun at 16,000 rpm for 2 min, and the supernatant was frozen on dry ice.
Immunoprecipitation was performed as described below. To the labeled lysate, 300 l of Net Gel buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl 0.1% Nonidet P-40, 1 mM EDTA, 0.25% gelatin, 0.02% sodium azide) (53) was added with the phosphatase and proteinase inhibitors in the concentrations listed above. The lysate was first precleared using 100 l of a 10% solution of fixed Staphylococcus aureus protein A-positive cells (Roche Molecular Biochemicals) in Net Gel buffer for 1 h while rolling at 4°C. The lysate was then spun down twice to eliminate all solid material. 5 mg of anti-FLAG M5 monoclonal antibody from Sigma was added to immunoprecipitate the protein of interest for 16 h at 4°C. The antibody was brought down using 50 l (packed volume) of protein A-Sepharose Fast Flow (Amersham Pharmacia Biotech) that had previously been washed with the Net Gel buffer containing proteinase and phosphatase inhibitor mix described above. This incubation was performed for 1 h at 4°C before being washed with 130 l of radioimmune precipitation buffer containing proteinase and phosphatase inhibitor mix three times for 30 min each. The proteins were eluted using Laemmli buffer at 95°C for 10 min. One-half the volume of eluted material was run on a Tris-glycine-SDS-10% polyacrylamide gel and visualized by autoradiography.
Western Blot Analysis-Antibodies against FLAG (anti-FLAG M5 monoclonal antibody from Sigma) or hemagglutinin (12CA5 from (Roche Molecular Biochemicals)) were used at concentrations recommended by the manufacturer.
In Vitro Kinase Reactions and Phosphoamino Acid Analysis-Recombinant TFIIA (100 ng) was incubated with ϳ10 ng of affinity-purified HA-tagged TAF II 250 or HA-tagged TFIID in a reaction volume of 15 l containing 12.5 mM Hepes, pH 7.9, 12.5% glycerol, 0.4 mg/ml bovine serum albumin, 6 mM MgCl 2 , 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, and phosphatase inhibitor mix described above. Reactions were incubated at 30°C for 30 min. Phosphorylated proteins were subject to phosphoamino acid analysis essentially as described (54).
RESULTS
The amino-terminal (␣) and carboxyl-terminal (␤) domains of the large subunit of TFIIA (␣␤) are highly conserved between human and yeast (Fig. 1A) . In previously published work, we had shown that yeast TOA1 subunit of TFIIA was phosphorylated in vivo, and alanine substitution of serines 220, 225, and 231 abrogated TFIIA phosphorylation. Alignment of the carboxyl-terminal domain of TOA1 with the ␣␤ subunit of TFIIA shows that yeast serine 225 and 230 can be partially aligned with human serine residues 316 and 321 (Fig. 1B) . To determine if human TFIIA was similarly phosphorylated in human cells, FLAG-tagged TFIIA ␣␤ was transfected into 293 cells and assayed for incorporation of phosphate by metabolically labeling transfected cells with [ 32 P]orthophosphate. We found that TFIIA ␣␤ was efficiently labeled under these conditions, while the tightly associated heterodimeric partner TFIIA ␥ was not labeled in these experiments (Fig. 2 and data not shown) . To determine if the serine residues conserved between yeast and human TFIIA large subunits were important for phosphorylation in vivo, we mutated two sets of serine residues in TFIIA ␤ domain, Ser 280 /Ser 281 and Ser 316 /Ser 321 to alanines. FLAGtagged TFIIA wild type and serine to alanine mutants were transfected into 293 cells, metabolically labeled with [ 32 P]orthophosphate, and assayed by immunoprecipitation (Fig. 2, upper panel) . We found that alanine substitutions at serines 316 and 321 reduced phosphorylation of TFIIA considerably, while a mutation in serines 280 and 281 had only a small effect on in vivo phosphorylation. Alanine substitution at all four positions (S280A/S281A/S316A/S321A) produced the most dramatic reduction of TFIIA phosphorylation. All of the TFIIA ␣␤ proteins were expressed to similar levels in transfections and after immunoprecipitations as determined by Western blot analysis (Fig. 2B, lower panel, and data not shown) . These results indicate that human TFIIA ␣␤ can be phosphorylated in vivo and that serine residues 316 and 321 are important for this phosphorylation.
TAF II 250 has been reported to phosphorylate TFIIA in vitro (35) . We compared the ability of affinity-purified holo-TFIID and baculovirus-expressed TAF II 250 to phosphorylate TFIIA in vitro (Fig. 3) . Both holo-TFIID (hIID) and TAF II 250 were capable of phosphorylating TFIIA ␣␤ in vitro (Fig. 3A, lanes 2 and  4) . To determine if TFIIA ␣␤ was phosphorylated on the carboxyl-terminal domain in vitro, we tested the ability of TAF II 250 and hIID to phosphorylate the ␤ subunit of TFIIA when presented as the trimeric form of TFIIA (referred to as ␣ ϩ ␤ ϩ ␥). Both hIID and TAF II 250 preferentially phosphorylated the ␤ subunit of TFIIA in the trimeric complex, although some background phosphorylation occurred on ␣ and ␥ (Fig. 3A,  lanes 6 and 8) . The phosphorylation of TFIIA ␤ by TAF II 250 and hIID is likely to be specific, since the ␤ subunit has six serine and five threonine residues, while the ␣ subunit has 11 serines and 17 threonines, and the ␥ subunit has five serines and nine threonines.
To determine if the ␣ and ␥ subunit of TFIIA were important for the TAF II 250 phosphorylation of TFIIA ␤, we expressed TFIIA ␤ as a GST fusion protein and assayed its ability to be phosphorylated in vitro by TAF II 250 (Fig. 3B) . We found that GST-␤-(252-375) was efficiently phosphorylated by TAF II 250 in vitro, while GST was not phosphorylated. To partially map the phosphorylation sites in vitro, we compared GST-␤-(252-376) to two amino-terminal truncation mutants GST-␤-(310 -376) and GST-␤-(329 -376). We found that TAF II 250 efficiently phosphorylated ␤-(310 -376) but failed to phosphorylate ␤-(329 -376), suggesting that important phosphoacceptor sites reside between amino acids 310 and 329 (Fig. 3B) . Phosphorylated TFIIA ␤ subunit was subjected to phosphoamino acid analysis to determine the predominant amino acid species phosphorylated (Fig. 3C) . We found that the majority of phosphorylation occurred on serine residues, although a trace of threonine phosphorylation was detected. Tyrosine phosphorylation was not detected. Identical observations were made when TFIIA ␣␤ was subject to phosphoamino acid analysis, indicating that serine is the predominant species phosphorylated throughout the entire polypeptide. To determine if the phosphorylation of TFIIA by TFIID-associated kinase was conserved between human and yeast, we compared the ability of hIID to phosphorylate human TFIIA ␣␤ with yeast TOA1 (Fig.  3D) . We found the human TFIID was similarly capable of phosphorylating yeast TOA1, suggesting that the conserved serine residues in TFIIA were important for phosphorylation.
The phosphorylation of TFIIA by TAF II 250 and hIID was further characterized in vitro by comparing the relative specificity of phosphorylation for the wild type and mutant TFIIA. We have previously shown that alanine substitution of serine residues 280/281/316/321 in TFIIA ␣␤ abrogated phosphorylation in vivo (Fig. 2) . To determine if the same serine residues in TFIIA ␣␤ were required for phosphorylation by TFIID and TAF II 250 in vitro, we compared TFIIA wild type (wt IIA) and S280A/S281A/S316A/S321A mutant (m-IIA) in the in vitro kinase reaction (Fig. 4) . TAF II 250 phosphorylated wild type TFIIA efficiently but had little activity on mutant IIA (Fig. 4A,  lanes 3 and 4) . Similarly, holo-TFIID phosphorylated wild type TFIIA efficiently but had no detectable kinase activity with mutant IIA (Fig. 4A, lanes 5 and 6) . In contrast, commercial preparations of casein kinase II phosphorylated wild type TFIIA and mutant IIA to similar levels (Fig. 4A, lanes 7 and 8) , suggesting that sequence specificity is different for TAF II 250 kinase and casein kinase II. Equal amounts of wild type TFIIA and mutant IIA were included in these reactions as shown by Coomassie staining of SDS-PAGE gels (Fig. 4B) . These results indicate that TAF II 250 is a better candidate for phosphorylation of TFIIA ␣␤ in vivo than is casein kinase II, since mutant IIA is poorly phosphorylated in vivo.
TAF II 250 consists of two functional and distinct kinase domains. We tested the ability of the NH 2 -terminal kinase (NTK) domain to phosphorylate TFIIA in vitro (Fig. 4C) . TAF II 250 NTK was expressed and purified as a GST fusion protein from baculovirus-infected cells. NTK activity was demonstrated by phosphorylation of the TFIIF subunit RAP74 (Fig. 4C, lane 1) . We then compared the ability of TAF II 250 NTK to phosphorylate mutant IIA or wild type TFIIA in the presence of RAP74 (Fig. 4C, lanes 2 and 3) . We found that TAF II 250 NTK preferentially phosphorylated wild type TFIIA relative to mutant IIA, although the activity was significantly less than found in full-length TAF II 250. These results suggest that the NH 2 -terminal kinase domain of TAF II 250 can phosphorylate TFIIA with specificity similar to that observed for full-length TAF II 250 and hIID.
The Rb tumor suppressor has been shown to inhibit TAF II 250 kinase activity directed toward RAP74 in vitro (37) . A mutation in Rb (Rb⌬ex22) that abrogates tumor suppressor activity was shown to be incapable of inhibiting TAF II 250 kinase activity. We tested the ability of GST, GST-Rb, and GSTRb⌬ex22 to inhibit the phosphorylation of TFIIA by TAF II 250 (Fig. 4D, lanes 1-3) . Similar to what was found for the phosphorylation of RAP74, we found that Rb but not Rb⌬ex22 could inhibit TFIIA ␣␤ phosphorylation. Concentrations of GST, GST-Rb, and GST-Rb⌬ex22 were shown to be equivalent by Coomassie staining of SDS-PAGE gels (Fig. 4D, lanes 4 -6) . The inhibition of TFIIA phosphorylation by Rb further suggests that TFIIA is phosphorylated by TAF II 250 and not by a contaminating activity in the affinity-purified baculovirus preparation of TAF II 250.
TFIIA Phosphorylation Correlates with Transcription Stimulation-To determine if TFIIA phosphorylation was important for transcription function, we employed a transient transfection assay (Fig. 5) . Wild type or mutant ␣␤ was cotransfected with equimolar amounts of TFIIA ␥ and assayed for the stimulation of reporter activity. Western blots were used to confirm that both ␣␤ and m␣␤ were expressed in vivo at equal levels (data not shown). TFIIA subunits were tested for their ability to affect transcription activated by GAL4-E2F, GAL4-EWS, GAL4-VP16, or GAL4-MYC on the G5-TK-Luc promoter construct (Fig. 5A) . In all cases, wild type ␣␤ stimulated transcription between 2-and 3-fold. Wild type TFIIA stimulated Zta activation of the Z 5 E4TCAT promoter almost 4-fold, while mutant ␣␤ had no detectable activation (Fig. 5B) . Similarly, wild type ␣␤ (wt-␣␤) stimulated the cyclin D1-Luc reporter, while mutant ␣␤ (m-␣␤) had no effect (Fig. 5C ). These results indicate that transfection of TFIIA ␣␤ stimulates various activators and promoters, and this activation is dependent upon serine residues shown to be essential for phosphorylation in vivo.
TFIIA Phosphorylation Strengthens the TBP⅐TFIIA Complex-Previous work with yeast TFIIA indicated that phosphorylation of TOA1 stimulated T-A complex formation in EMSA. We tested the effect of human TFIIA phosphorylation on the T-A complex. We found that phosphorylation had no detectable effect on wild type TFIIA (Fig. 6A, lanes 3 and 4) . However, the increase in stability induced by phosphorylation may not be detectable unless the primary contact between TFIIA and TBP is compromised. To test this possibility, we assayed the effect of phosphorylation on a TFIIA derivative containing an alanine substitution at ␥-Tyr 65 . TFIIA ␥-Tyr 65 is the primary contact in the crystal-determined structure, and mutagenesis of this residue severely compromises T-A formation in EMSA (44) . IIA-␥Y65A was significantly reduced for T-A complex formation in the absence of phosphorylation (Fig. 6A, lanes 5 and 7) . However, in the presence of ATP and casein kinase II, IIA-␥Y65A was strongly stimulated in forming the T-A complex (Fig. 6A,  lanes 6 and 8) . To determine if the serine residues in TFIIA ␣␤ were required for this stimulation of T-A complex formation, we compared wild type ␣␤ (IIA-Y65A) with ␣␤ lacking all four phosphoserine residues (mIIA-Y65A) in EMSA reactions (Fig.  6B) . We found that phosphorylation stimulated the T-A complex with wild type ␣␤ (Fig. 6B, lanes 1 and 2) but did not stimulate complex formation with mutant ␣␤ (Fig. 6B, lanes 3  and 4) , indicating that stimulation by ATP and CKII was dependent upon the phosphoacceptor serine residues in TFIIA ␣␤. These results were found to be essentially identical when TAF II 250 was used as the kinase (Fig. 6C) , but the efficiency of TAF II 250 phosphorylation is significantly less than that of CKII in these reactions. The reduced complex formation in the presence of TAF II 250 results partly from the inhibitory activity of TAF II 250 on TBP-DNA and TBP-TFIIA interactions (26, 55) . Together, these results suggest that TFIIA phosphorylation by 
TFIIA Phosphorylation Is Conserved between Yeast and
Humans-Human and yeast TFIIA share significant sequence similarity in the amino-and carboxyl-terminal domains of the large subunits. The intervening spacer region has no known function but is important for normal growth in yeast. The region of yeast TFIIA that we have found to be phosphorylated (TOA1 amino acids 220 -232) is essential for viability but is only partially conserved with human TFIIA (19) . Only one of the serine residues can be aligned with human TFIIA, although several other serines are similarly positioned in acidic patches. This domain of TFIIA could not be visualized in the crystal structure, presumably because this domain lacks ordered structure in the ternary complex. Our results suggest that phosphorylation of TFIIA in this domain is a conserved posttranslation modification that promotes additional contacts with TBP that are important for transcription functions.
TAF II 250 NTK Is a Candidate TFIIA Kinase-We have shown that TAF II 250 can phosphorylate TFIIA in vitro (Figs. 3  and 4) . Phosphorylation was mapped to serine residues on the ␤ subunit between amino acid residues 310 and 329. Alanine substitution of serine residues 316 and 321 strongly reduced TFIIA phosphorylation and, in combination with alanine substitutions at serines 280 and 281, completely eliminated detectable phosphorylation by affinity-purified TFIID or TAF II 250. The specificity of serine phosphorylation by TAF II 250 in vitro corresponds well to the serine phosphorylation specificity found in vivo (Fig. 2) . Interestingly, we found that Rb, but not the tumor suppressor-defective mutant Rb⌬ex22, could inhibit TAF II 250 phosphorylation of TFIIA in vitro. These experiments support earlier studies demonstrating that Rb can inhibit TAF II 250 phosphorylation of RAP74 (37) . Considering the fact that TFIIA has been implicated in regulating cell cycle progression in yeast, it is possible that TAF II 250 phosphorylation of TFIIA may be a transcription regulatory signal required for stimulation of cell cycle control genes (22) . Consistent with this hypothesis is the observation that TFIIA phosphorylation-defective mutants were incapable of stimulating transcription from the cyclin D1 promoter (Fig. 5) . Transfection of cyclin D1 bypasses the TAF II 250-dependent cell cycle defect found in ts13 cells, suggesting that cyclin D1 is a target of TAF II 250 activation (56) . Our results are consistent with these findings and further suggest that TFIIA contributes to the regulation of cyclin D1 presumably by TAF II 250 phosphorylation of TFIIA.
A second line of evidence that TAF II 250 may positively regulate TFIIA comes from genetic studies in yeast (23) . Deletion of the amino-terminal domain of yeast TAF II 145 (the homologue of human TAF II 250) results in temperature-sensitive growth. This deletion is predicted to abolish both the TBP interaction domain and the NH 2 -terminal kinase domain, although no kinase activity in yeast TAF II 145 has been reported. This deletion mutant can be suppressed by high copy expression of both subunits of TFIIA (23) . Increased expression of TFIIA may be predicted to bypass the need for phosphorylation by increasing the effective concentration of TFIIA and therefore driving the TFIIA-TBP association forward by mass action. These observations from yeast genetics are consistent with our model that the amino-terminal domain of TAF II 250 promotes TFIIA⅐TBP complex formation. While we and others have also found that TAF II 250 can inhibit TBP-TATA binding and TFIIA-TBP binding, these processes must be dynamic in vivo (25, 26) . It is possible that TAF II 250 inhibits unphosphorylated TFIIA from binding TBP but that phosphorylation of TFIIA is sufficient to reverse this inhibition. In this way, TAF II 250 can function both to inhibit and promote TFIIA⅐TBP complex formation depending on the phosphorylation status of TFIIA.
Regulation of Transcription by TFIIA Phosphorylation-We show that a phosphorylation-defective mutant of TFIIA can not stimulate transcription in transient transfection assays, while wild-type TFIIA can stimulate most activators and promoters 2-4-fold (Fig. 5 ). While these activation levels are modest, they are similar to the levels of activation typically observed for cotransfection of coactivators like CBP/p300. Phosphorylation of TFIIA stabilized the T-A complex when TFIIA mutants compromised in TBP binding were used (Fig. 6 ). This suggests that TFIIA phosphorylation stabilizes T-A complex formation either by increasing affinity of TFIIA for TBP through the ␥-Tyr 65 contact or by enhancing the interaction between the unstructured domain of TFIIA with TBP. Since this increase in stability is only detectable in the yeast ternary complex or in mutated human TFIIA (␥Y65A), we suggest that stabilization of the ternary complex is not the major function of phosphorylation. Rather, we suggest that interaction of phosphorylated TFIIA with TBP may alter the interaction between coactivators and repressors and TBP. This could be a method of regulating preinitiation complex assembly and disassembly as well as promoter clearance and transcription reinitiation cycles. Future studies will be required to determine how TFIIA phosphorylation regulates the transcription process.
